New Therapies to Bolster Asia-Pacific’s Rheumatoid Arthritis Market - Ken Research

Rheumatoid arthritis (RA) is a chronic, progressive and incurable auto-immune disease that majorly affects the joints in a human body. It is identified by synovial inflammation and gradual bone erosion over the years. The major symptoms are stiffness, pain in hands and feet and obstruct a patient’s mobility. Lack of medical help will result in joint destruction and disability. Any patient suffering from rheumatoid arthritis requires continuous treatment that is relatively very expensive. Therefore, rheumatoid arthritis therapeutic market is highly competitive due to increasing number of new drug approvals. Competition is fierce in the therapeutic market among TNF-α inhibitors for patients who are refractory to traditional disease-modifying anti-rheumatic drugs (DMARD).

Majority of the rheumatoid arthritis patients do not respond when treated with TNF-α inhibitors. Therefore, small-molecule DMARDs such as the Janus kinase (JAK) inhibitor and Xeljanz (tofacitinib) replace the ineffective TNF-α inhibitors. Xeljanz is very effective because it reduces the risk of developing cardiac diseases such as heart attack and stroke in patients. Xeljanz is an orally administered small-molecule drug which is used as a second-line treatment for rheumatoid arthritis patients who do not respond to methotrexate, and as a third-line therapy for rheumatoid arthritis patients who do not respond to biologics.

According to the study “Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023-Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs”, in Asia-Pacific region, there is a need to improve safety in the therapeutic category. Elevated rates of infection were observed due to frequent consequences of the immune-suppression involved in treatments. Therefore, biological therapies are not recommended to patients who are susceptible to any infection. There is a need to create biologics with more convenient and less invasive drug-delivery methods because the existing therapies for rheumatoid arthritis are administered subcutaneously or intravenously. Such drug delivery methods in rheumatoid arthritis patients are frequently associated with pain, rash, and allergic reactions at the injection or infusion site, in the case of infusion, flu-like illness, fever, chills, nausea, and headache. There is a need to develop convenient and safe drug administration procedures for rheumatoid arthritis patients.

Advanced medical technology has witnessed great changes in the field of diagnostic technology to strengthen the performance of rheumatoid arthritis drug manufacturers in Asia-Pacific region. The new products in the Asia-Pacific rheumatoid arthritis market are Sirukumab, an antiIL6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an antiIL6 humanized IgG4 mAb; and RCT18, a recombinant human Blymphocyte stimulating factor (BLyS) receptor antibody fusion protein.

With the recently approved rheumatoid arthritis therapies along with new therapies are sure to drive the rheumatoid arthritis therapeutics market in Asia-Pacific. The promising pipeline companies are Johnson & Johnson (J&J), GlaxoSmithKline (GSK)'s sirukumab, and Galapagos's filgotinib. The leading players in rheumatoid arthritis therapeutics market are AbbVie, Amgen, Amgen, Daiichi Sankyo, Biogen Idec, Genentech, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Regeneron, Sanofi, Roche and UCB.

India, Australia, China, South Korea and Japan are the leading consumers in Asia-Pacific (APAC) rheumatoid arthritis therapeutics market. Japan accounted for a majority share of the market, followed by China, Australia, India and South Korea. The introduction of biologic disease modifying antirheumatic drugs (DMARD) has helped in the growth of the rheumatoid arthritis (RA) market in Asia-Pacific tremendously over the last two decades. This growth is expected to continue at a moderate pace in the next few years.

To know more, click on the link below:

https://www.kenresearch.com/healthcare/general-healthcare/rheumatoid-arthritis-therapeutics-in-asia-pacific-markets-to-2023-novel-jak-and-il-6-receptor-inhibitors-to-stimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-anti-tnfs/149110-91.html

Related Reports:

https://www.kenresearch.com/healthcare/general-healthcare/osteoarthritis-pipeline-review/143930-91.html

https://www.kenresearch.com/healthcare/pharmaceuticals/osteoarthritis-pipeline-review-h2-2017/142124-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

0124-4230204

Chronic Cardiac Diseases To Drive Canada’s Prosthetic Heart Valves Market-Ken Research

According to the study “Canada Prosthetic Heart Valves Market Outlook to 2025”, the increasing incidences of chronic heart valve-related disorders such as cardio valvular diseases, valvular and heart failure, various heart disorders, arterial diseases and increase in aged population are driving the demand for cardiac prosthetic devices in Canada. Also, the rising incidence of chronic heart diseases among infants is driving the need for surgery and catheterization to correct the damaged heart valves.

Prosthetic heart valve is a device implanted in the human heart that suffers from valvular heart disease. The diseased valve is replaced with a prosthetic heart valve which results in reduction in morbidity and mortality related to cardiac valve disorders. If the heart valve disease treatment reaches an extreme point, then a surgery is recommended to repair or replace the valve. The replaced prosthetic heart valves are carbon based mechanical valves and biological tissue valves. Technological advancements, increasing rate of heart valve diseases and increasing aged population are few factors driving the growth of prosthetic heart valve market in Canada.

Prosthetic heart valves market is categorized based on products such as transcatheter heart valves, tissue heart valves, mechanical heart valves, aortic valves, mitral valves, biological heart valves, aortic valves, mitral valves, pulmonary valves, tricuspid valves, aortic valves, mitral valves and pulmonary valves. Canadian prosthetic heart valves market is moderately fragmented due to the presence of numerous large and small vendors. The leading players are Abbott Laboratories, Boston Scientific, Edwards Lifesciences, LivaNova, Lepu Medical Technology, and Medtronic.

The increasing incidences of various chronic diseases such as high blood pressure, diabetes and developed healthcare infrastructure within the country are encouraging the development and manufacture of new technological advanced prosthetic heart valve devices. The advanced design and materials are creating a positive opportunity for the adoption of prosthetic heart valve devices in the hospitals making replacement surgeries smooth due to excellent valve performance, safety, and durability. There are various opportunities in the Canadian prosthetic heart valve market due to advance surgical replacement technologies. The high cost of transcatheter aortic valve replacement devices along with stringent regulations may hamper the growth of the Canadian prosthetic heart valve market over the next few years.

To know more, click on the link below:

https://www.kenresearch.com/healthcare/medical-devices/canada-prosthetic-heart-valves-market-outlook-to-2025/149184-91.html

Related Reports:-

https://www.kenresearch.com/healthcare/medical-devices/mexico-prosthetic-heart-valves-market-outlook-to-2025/149388-91.html

https://www.kenresearch.com/healthcare/medical-devices/australia-prosthetic-heart-valves-market-outlook-to-2025/149386-91.html

Contact Us:-

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

0124-4230204

India Corrugated Box Market is Driven by Rise in Demand from Fresh Food and Beverages, Logistics Application, Increasing Consumer Awareness Towards Sustainable Packaging and Growth of the E-Commerce Industry: Ken Research

Rising demand of safe and cushioned packaging of the product along with the rise in FMCG, home & personal care goods, electronic goods industries has driven the growth of corrugated boxes in the country.

Analysts at Ken Research in their latest publication “India Corrugated Box Market Outlook to 2023 – by Ply/Box Type (3ply, 5ply, 7ply and 9ply), by End User (FMCG, Automotive, Textile, Electronics & Appliances and Others), by Slotted, Die-Cue Box and Others” believe that promoting better regulations, procurement of automatic and updated technology machines from different countries and improved marketing strategies followed by companies will aid the corrugated box market. 
                                         
India corrugated box market is in its growth phase. Though, the craft papers prices are increasing but the demand for sustainable and safe packaging of goods is also increasing therefore new players are entering the market. Demonetization had hit the industry badly, and has also led to fall in demand for corrugated boxes as a result of slow movement of FMCG & other consumer goods from the retail counters which led to retrenchment of work force & financial losses for the industry. Despite, increase in prices of raw material in the year 2015, the production of corrugated boxes has increased at a sizeable growth rate. However, in order to increase the market growth the Indian Corrugated Case Manufacturers Association (ICCMA) and Automatic Board Plants & Western India Corrugators Box Manufacturers’ Association (WICMA) supported to grant a minimum of 12% price increase on boxes so that the Box industry is able to cover supplies of Craft Paper well in time to avoid any disruptions in the supply chain. Moreover, the industry introduced new heavyweight products such as billerud flute semi-chemical fluting. Primarily, targeted at replacing wooden packaging, this product is also able to replace double-walled board with an overall lighter weight single wall substitute.

For more information on the research report, refer to below link:
https://www.kenresearch.com/automotive-transportation-and-warehousing/logistics-and-shipping/india-corrugated-box-market/149477-100.html

Related Reports:
https://www.kenresearch.com/automotive-transportation-and-warehousing/logistics-and-shipping/us-paperboard-packaging-industry/47688-100.html
The paper board packaging market will record revenue of USD 66 Billion by 2020 due to more players entering the market, expansion of e-commerce sector in the country, increasing demand of personal care & health care products.

https://www.kenresearch.com/automotive-transportation-and-warehousing/logistics-and-shipping/india-paper-packaging-market-research-report/605-100.html
The paper packaging industry is largely comprised of unorganized players. There are a few large players such as TCPL, ITC, Parksons Packaging, and others.

https://www.kenresearch.com/metal-mining-and-chemicals/chemicals/india-recycling-pet-market-research-report/586-101.html
The future prospects of India Recycling PET Industry are impressive on the groundwork of an increase in disposable income fueled by growth in youth population that marked an increase in the availability of post consumer recycled PET waste bottles.

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249

Bio-Absorbable Stents to Encourage Growth in Brazil Peripheral Vascular Devices Market-Ken Research

According to the study “Brazil Peripheral Vascular Devices Market Outlook to 2025”, the rising prevalence of peripheral vascular disorders, diabetes and obesity in the Brazilians has led to a huge demand for stent implants. The increasing consumption of junk food and smoking has increased the risk of stroke due to formation of atherosclerotic plaques with high calcification in peripheral blood vessels. The advanced technology in stents has assisted in overcoming in-stent restenosis complications due to neointima hyperplasia and neovascularization at the site of implant. These factors are responsible for the growth in market penetration of stents utilized for treatment of peripheral vascular diseases.

Peripheral vascular disease is a condition in a human body that determines a damage or blockage in the peripheral blood vessels. It can also cause blood clots such as deep vein thrombosis, inflammation, or narrowing and blockage of the blood vessels. The various devices used for the treatment of peripheral vascular diseases are Aortic Stent Grafts, Arteriotomy Closure Devices, Carotid and Renal Artery Stents, Inferior Vena Cava Filters (IVCF), Peripheral Embolic Protection Devices, Peripheral Guidewires, Peripheral Vascular Stents, PTA Balloons Catheters, PTA Peripheral Drug Eluting Balloons (DEB) Catheters, Renal Denervation Catheters, Tip Location Devices and Vascular Grafts.

The increasing incidences of peripheral vascular disease among the Brazil population are driving the peripheral vascular devices market. The peripheral vascular devices market is highly fragmented due to multiple players. The leading players in Brazil’s peripheral vascular devices are Medtronic plc, Abbott Laboratories, Boston Scientific Corp. and others.

With the ongoing development in sophisticated healthcare infrastructure, health awareness, increase in healthcare expenditure and increasing R&D pertaining to drug discovery and development are few factors accounting for the growth in Brazil’s peripheral vascular devices market. Modernization and increasing aged population in Brazil has increased the rate of peripheral vascular diseases. In addition, the presence of untapped growth opportunities in Brazil has increased health awareness which boosted the growth in the peripheral vascular devices market. The latest market trend is the increasing use of bio-absorbable stents in the treatment of peripheral vascular disease.

To know more, click on the link below:

https://www.kenresearch.com/healthcare/medical-devices/brazil-peripheral-vascular-devices-market-outlook-to-2025/149182-91.html

Related Reports

https://www.kenresearch.com/healthcare/medical-devices/vietnam-medical-devices-market/143604-91.html

https://www.kenresearch.com/healthcare/medical-devices/indonesia-medical-devices-market/143545-91.html

Contact Us:-

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

0124-4230204

UK Population Interested in Renewable Energy Compare to Nuclear Power - Ken Research

United Kingdom possesses 16 reactors that generate one sixth of the country’s power and no new nuclear plants were constructed in the recent years. The country has decided to decommission the existing nuclear fleet over the next few years as the maintenance cost is increasing drastically. UK government subsidies and support were always a part of the nuclear industry since initiation. The government provides waste disposal services for spent fuel and intermediate-level nuclear wastes. It was observed that there is an increasing construction cost of nuclear storage facilities due to many uncertainties associated with the costs of waste disposal.

The cost of clean-up from nuclear accidents is majorly covered by the government. However, the probability of any nuclear accident is very difficult to calculate because the modern reactors are often claimed to be safer than previous generation reactors. The government’s nuclear power subsidies in the United Kingdom represents an enormous opportunity cost, shaping the country’s energy system for several generations and preventing the country from investing in other renewable energy technologies. All the nuclear power plants are cost-effective, reliable, low carbon electricity system which supports the country’s needs to secure its prosperity. The leading companies in the United Kingdom’s nuclear power are NuGeneration Ltd, Horizon Nuclear Power, EDF Energy Nuclear Generation Group Limited, and China General Nuclear Power Corp.

According to the study “Nuclear Power in United Kingdom, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles”, United Kingdom may enter a new phase of nuclear power development in the next few years because nuclear energy production is expected to increase by one third more than the current production by the year 2035. UK has a total of 15 operational nuclear reactors at seven established plants with 14 advanced gas-cooled reactors, one pressurised water reactor and one nuclear reprocessing plant. Life-extensions in the advanced gas-cooled reactors are carried out to enhance more nuclear power production.

UK has announced that they would withdraw the development of new nuclear power plants in view of creating low carbon economy. The national survey on UK’s nuclear energy issues was found to be relatively low because majority of them preferred renewable energy over nuclear energy. Leukaemia and non-Hodgkin’s lymphoma cases were discovered in population residing near nuclear plants by the United Kingdom Committe on Medical Aspects of Radiation in the Environment. Therefore, there is a huge demand for wind power compared to the nuclear energy.

Earthquakes are relatively frequent in UK at a magnitude less than 6.5 but do not cause any destruction to the well-constructed nuclear structures. UK will expect extreme climatic conditions but less of tsunamis according to Energy and Climate Change Select Committee. The majority of the UK’s greenhouse gas emissions are generated from production and consumption of any source of energy such as driving cars, manufacturing goods or simply boiling a kettle. Majority of the UK population are keen to meet the carbon targets by becoming energy efficient and by switching to low-carbon fuels. More than fifty percent of the UK population are supporting nuclear power combined with renewable technologies along with energy policy and the rest of the population is expecting power from renewable resources in the next 15 years.

To know more, click on the link below:

https://www.kenresearch.com/defense-and-security/weapon/nuclear-power-in-united-kingdom-market-outlook-to-2030-update-capacity-generation-investment-trends-regulations-and-company-profiles/149205-16.html

Related Reports

https://www.kenresearch.com/defense-and-security/weapon/nuclear-power-in-china-market-outlook-to-2030-update-capacity-generation-investment-trends-regulations-and-company-profiles/149204-16.html

https://www.kenresearch.com/energy-and-utilities/power/nuclear-power-in-mexico-market-outlook/142689-103.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

0124-4230204

Global Competitors Introducing Various Cognitive Impairment Disorder Drugs to Boost Market Growth - Ken Research

Cognitive impairment is not an illness, but a condition of the body. The patient has trouble with memory or paying attention, trouble speaking or understanding, difficulty in recognising people, places or things, and might find new places or situations overwhelming. Cognitive impairment patient is confused, agitated, or very moody. This situation can come and go which is known as delirium. The cognitive impairment disorder can be mild, or severe, or anything in between, temporary problem or a permanent condition. The major causes of temporary cognitive impairment are infections, such as a urinary tract infection or pneumonia, vitamin deficiency, dehydration, and reactions to medications. Few causes of permanent cognitive impairment are dementia, stroke and brain injury. Not every aged person will have cognitive impairment; however, cognitive impairment is more common in older people. It can be both genetic and acquired, and brain damage caused via accidents.

According to the study “Cognitive Impairment Disorders Drug Development Pipeline Review, 2018”, if left untreated, cognitive impairment disorder can worsen along with the possibility of other mental problems; therefore, various treatment options and a wide range of drugs are available. Globally, therapeutics or drugs for cognitive impairment are still under development. The key players involved in therapeutic or drug development for cognitive impairment are associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease.

Drugs for cognitive impairment disorders are small molecules, due to their ability to cross the blood-brain barrier and their proven commercial success. Majority of products are neuromodulators, impacting the dopaminergic, serotonergic and glutamatergic systems. There is diversity within each drug in terms of molecule type and molecular targets. Human central nervous system (CNS) is complex and highly sophisticated in nature. Pathophysiology of cognitive impairment disorders is not well understood in the medical sciences. Therefore, treatment options are limited, and the available drugs in the market act by slowing the disease progression or treating symptoms.

The various drugs still under development for cognitive impairment disorders are above 800, respectively. The leading players in the global cognitive impairment disorders drugs development are Eli Lilly and Co., Bristol-Myers Squibb, Pfizer, AstraZeneca, AB Science SA, AbbVie Inc, Aucta Pharmaceuticals LLC, Avineuro Pharmaceuticals Inc, CereSpir Inc, CHA Bio & Diostech Co Ltd, CohBar Inc, Connexios Life Sciences Pvt Ltd, Cypralis Ltd, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, Dongkook Pharmaceutical Co Ltd, Dr. August Wolff GmbH & Co KG Arzneimittel, Echo Pharmaceuticals BV, Eisai Co Ltd, Epigen Biosciences Inc, GlaxoSmithKline Plc, Golden Biotechnology Corp, Grifols SA, ID Pharma Co Ltd, Immungenetics AG, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Merck & Co Inc, Microlin Bio Inc, ModGene Pharma LLC, Octapharma AG, Oryzon Genomics SA, Otsuka Holdings Co Ltd, Ovensa Inc, Prevacus Inc, ProMIS Neurosciences Inc, and Voyager Therapeutics Inc.

It was observed that cognitive impairment disorders will increase significantly over the next few years due to increase in aging population. Therefore, there is a strong need to develop new drugs that effectively treat symptoms and target the underlying mechanisms of disease. The advanced technology in medical sciences is encouraging cognitive impairment disorders drug development worldwide. With more players in this category, more variants of drugs are introduced for the treatment of cognitive impairment disorders. This trend will continue over the next few years due to increasing instances of cognitive impairment disorders among all age groups.

To know more, click on the link below:

https://www.kenresearch.com/healthcare/general-healthcare/cognitive-impairment-disorders-drug-development-pipeline-review/149105-91.html

Related Reports:

https://www.kenresearch.com/healthcare/pharmaceuticals/pharmapoint-painful-diabetic-neuropathy-global-drug-forecast-and-market-analysis-to-2026/149179-91.html

https://www.kenresearch.com/healthcare/pharmaceuticals/mitogen-activated-protein-kinase-14-cytokine-suppressive-anti-inflammatory-drug-binding-protein-or-mitogen-activated-protein-kinase-p38-alpha-or-map-kinase-mxi2-or-max-interacting-protein-2-or-stress-activated-protein-kinase-2a-or-mapk14-or-ec-2-7-11-24-/149141-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

0124-4230204

India Corrugated Box Market is expected to reach over INR 63,000 Crore by FY’2023: Ken Research

India corrugated box market segmentation by type of ply/box (3ply, 5ply, 7ply and 9ply), by end user (FMCG, Automotive, Textile, Electronics & Appliances and Others), by states (Gujarat, Maharashtra, Himachal, Tamil Nadu, West Bengal, UP and Others), by type of box (Slotted, Die-Cue and Others), by type of Box (Colored and Non-colored), by type of players (Organized and Un-organized) and by type of sales (Domestic and Exports), company profile of major players (Horizon Packs Pvt. Ltd, Worth Peripherals, Supack Pvt. Ltd, TGI Packaging Pvt. Ltd, Jayaraj Fortune Packaging Pvt. Ltd, OJI India Packaging Pvt. Ltd, CEL Packaging, Hariwansh Packaging, CJ Corporation, Paper Containers India, Wadpack Pvt. Ltd, Chaitanya Packaging Pvt. Ltd., BL Containers Pvt. Ltd.)

Analysts at Ken Research in their latest publication “India Corrugated Box Market Outlook to 2023 – by Ply/Box Type (3ply, 5ply, 7ply and 9ply), by End User (FMCG, Automotive, Textile, Electronics & Appliances and Others), by Slotted, Die-Cue Box and Others” believe that promoting better regulations, procurement of automatic and updated technology machines from different countries and improved marketing strategies followed by companies will aid the corrugated box market.

India corrugated box market is expected to register positive CAGR of around 21.8% during the period FY’2018-FY’2023. Use of corrugated for display/promotional packs, POPs and dispensers and the emergence of E-commerce industries are expected to have positive impact on the overall revenue of corrugated box market. 

• Increasing demand from fresh food and beverages, home & personal care goods, electronic goods industries will increase the reach of end users towards corrugated box manufacturers.
• Increasing the demand of safe and cushioned packaging of the product will augment the growth of India Corrugated box market.
• Rise in procurement of latest technology machines from China, Taiwan and other Asian countries by manufacturers in order to make production fast and accurate will also drive the future of India corrugated box industry

The growth in use of internet for shopping, stimulated by the growing use of smart phones as well as the increasing proportion of tech-savvy consumers, has a positive effect on corrugated demand, since it has direct influence on e-commerce market. Retail ready packaging is also increasing driven by the influence of supermarkets over the retail landscape and supported by their growing share of the retail market will also drive the corrugated box market in future. Inline Automatic board and box making plants will ease out the present semi automatic production processes and deployment of folder gluers, rotary die-cutters will grow in the future. Advances in multicolor, flexo printing will facilitate in-house flexo printing, do away with screen printing and contract printing on offset presses.
The trend of colored corrugated boxes has been on the rise. Several organized retailers are using colored and die-cut corrugated boxes for display and promotional purposes in their shops. These types of boxes are mainly used in order to attract customer’s attention as these boxes are very eye catching.

Companies Covered
Horizon Packs Pvt. Ltd, Worth Peripherals Ltd., TGI Packaging Pvt. Ltd., OJI India Packaging Pvt. Ltd., Jayaraj Fortune Packaging Pvt. Ltd., Supack Industries Pvt. Ltd., BL Containers Pvt. Ltd., Chaitanya Packaging Pvt. Ltd., CEL Packaging, Wadpack Pvt. Ltd., Hariwansh Packaging Pvt. Ltd., CJ Corporation and Paper Containers India Pvt. Ltd.

For more information on the research report, refer to below link:
https://www.kenresearch.com/automotive-transportation-and-warehousing/logistics-and-shipping/india-corrugated-box-market/149477-100.html

Related Reports:
https://www.kenresearch.com/automotive-transportation-and-warehousing/logistics-and-shipping/us-paperboard-packaging-industry/47688-100.html
The paper board packaging market will record revenue of USD 66 Billion by 2020 due to more players entering the market, expansion of e-commerce sector in the country, increasing demand of personal care & health care products.

https://www.kenresearch.com/automotive-transportation-and-warehousing/logistics-and-shipping/india-paper-packaging-market-research-report/605-100.html
The paper packaging industry is largely comprised of unorganized players. There are a few large players such as TCPL, ITC, Parksons Packaging, and others.

https://www.kenresearch.com/metal-mining-and-chemicals/chemicals/india-recycling-pet-market-research-report/586-101.html
The future prospects of India Recycling PET Industry are impressive on the groundwork of an increase in disposable income fueled by growth in youth population that marked an increase in the availability of post consumer recycled PET waste bottles.

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249